You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 31 - 40 of 26729 results
  1. RandD- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

    SBC: IMMUNETICS, INC.            Topic: NHLBI

    This project is aimed at the development of an enzyme immunoassay (ELISA) for screening blood for antibodies to Babesia microti. Human babesiosis is a malaria-like illness due to infection of red blood cells by various species of protozoan parasites belonging to the genus Babesia. Most human infections reported in the United States are caused by B. microti which is endemic in parts of the northeas ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Biomimetic Control of Flying Robots

    SBC: PHYSICAL SCIENCES INC.            Topic: A08056

    Physical Sciences Inc. (PSI) demonstrated in Phase I that it is possible to design a Micro Air Vehicle (MAV) which is robust to collisions by using techniques similar to what insects use to recover from collisions while still in flight. Observational studies of insects colliding with objects (high speed films of instrumented insects) conducted at the Harvard Microrobotics Laboratory show that the ...

    SBIR Phase II 2010 Department of DefenseArmy
  3. Immunoassay for diagnosis of Babesia infection

    SBC: IMMUNETICS, INC.            Topic: R

    DESCRIPTION provided by applicant In this Phase II project development and clinical validation of an ELISA test for in vitro diagnosis of Babesia microti infection will be completed Babesiosis is an emerging tick borne parasitic disease which may cause severe to fatal illness in immunocompromised or otherwise weakened patients and may be carried in the blood subclinically in up to of the ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Babesia antigen detection assay for blood screening

    SBC: IMMUNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Human babesiosis is a malaria like illness caused by infection of red blood cells by the protozoan parasite Babesia microti or related species primarily transmitted to humans through the bite of infected deer ticks Babesiosis can also be transmitted by blood transfusion and is currently acknowledged as the foremost unaddressed infectious risk to the US blood ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. VAMAV: Visual Collision Detection and Avoidance for a Micro Air Vehicle

    SBC: SCIENTIFIC SYSTEMS CO INC            Topic: AF06149

    This proposal presents the VAMAV system (Visual Awareness/Avoidance for a Micro Air Vehicle) for monocular visual collision detection and avoidance. Real time collision detection will be implemented using a time-to-collision approach based on area moment estimates of expansion from globally optimal image segmentation. This approach does not require explicit optical flow computations, and avoids n ...

    SBIR Phase II 2007 Department of DefenseAir Force
  6. DEVELOPMENT OF DIGITAL SATIORX, A VERY LOW COST REMOTELY CONTROLLABLE DISPOSABLE MICRONEEDLE TRANSDERMAL DRUG DELIVERY DEVICE ABLE TO DELIVER ANY LIQUID FDA APPROVED TRANSDERMAL DRUG

    SBC: SATIO INC            Topic: AH02

    The project plans to develop Digital SatioRx, a very low cost remotely controllable disposable microneedle transdermal drug delivery device able to deliver any liquid FDA-approved transdermal drug. Digital SatioRx's telemedicine-enabled (EHR-integrated), remotely activated, disposable design and unique delivery system will minimize infection risk and ensure administration of a reproducible drug do ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. DEVELOPMENT OF DIGITAL SATIORX, A VERY LOW COST REMOTELY CONTROLLABLE DISPOSABLE MICRONEEDLE TRANSDERMAL DRUG DELIVERY DEVICE ABLE TO DELIVER ANY LIQUID FDA APPROVED TRANSDERMAL DRUG

    SBC: TRITON SYSTEMS, INC.            Topic: AH02

    Triton Systems Inc. will create a transdermal microneedle patch and portable on-body pump system for therapeutic drug delivery for cardiovascular disease management (CVD) and intervention. The device will offer the capability for real-time remote management of therapeutic dosages by medical staff through communication with patient-specific electronic health records (EHRs), while remaining HIPAA-co ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. ARPA-H O1 SBIR PHASE II- NOVEL TELEHEALTH INSTRUMENTS FOR ASSESSING PEDIATRIC WELL-BEING. PROJECT TITLE: DIGITAL ASSESSMENT OF CHILDREN'S CONDITIONS USING ARTIFICIAL INTELLIGENCE (""DACCS AI"")

    SBC: BELLETORUS CORPORATION            Topic: AH01

    This project explores applying artificial intelligence (AI), transfer learning, and assessment of mobile phone images of pediatric throat, otoscopy ear, and skin conditions to help enable remote pediatric care of colds, sore throats, ear infections and other diseases.

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. TDP-43 aggregation inhibitors for the treatment of ALS

    SBC: Aquinnah Pharmaceuticals Inc.            Topic: 105

    Abstract Amyotrophic Lateral SclerosisALSis a universally fatal neurodegenerative disease that afflicts overout of everyindividualsProtein aggregation has been implicated as a primary driving force in ALS and multiple other neurodegenerative illnessesTDPis the principle component of the protein aggregates in ALSand TDPalso stands out as the only genetically defined ALS mutant gene that is also the ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Joining of Very Large, Low Cost Pultruded Advanced Composite Structures in Shipbuilding

    SBC: KaZaK Composites Incorporated            Topic: N02049

    KaZaK Composites proposes to design and demonstrate innovative, low cost pultrusion technology that meets DD(X) structural requirements, and could significantly reduce the finished cost of composite ship structures compared to VARTM. A database of design information is required to confidently commit to the use of a material in ship structures. It has been KCI's assertion that the pultrusion proce ...

    SBIR Phase II 2004 Department of DefenseNavy
US Flag An Official Website of the United States Government